Form 4 for DRMA Dermata Therapeutics, Inc.

Accepted 2025-01-23 00:00:00 ET · period of report 2025-01-21 · accession 0001654954-25-000693 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2025-01-23	2025-01-21	DRMA	FISHER MARY	Dir	A - Grant	—	+196.9K	196.9K	+207,212%	—
D	2025-01-23	2025-01-21	DRMA	FISHER MARY	Dir	A - Grant	—	+196.9K	196.9K	New	—

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2025-01-21	A	A	196,851	—	196,946	D	—	—	(F2) The purchase price per share of Common Stock and accompanying Warrant was $1.27.
2	Derivative	Warrant (Right to Buy)	2025-01-21	A	A	196,851	—	196,851	D	$1.27 · — to —	196,851 Common Stock	(F2) The purchase price per share of Common Stock and accompanying Warrant was $1.27. (F3) The Warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of Common Stock issuable upon exercise of the warrants. The Warrant will expire five years from the effective date of stockholder approval. The Warrant cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to such exercise, subject to certain exceptions.